A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

Study Summary

This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which doses of GLPG5101 work best with the least number of side effects. * In the second phase, participants will receive the selected dose(s) based on the results in the first phase.

Conditions

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell

Interventions / Drugs

GLPG5101

View on ClinicalTrials.gov ↗

Sponsor

GLPG

Galapagos NV

JAK Fibrosis Inflammation

F21/100

Study Details

Enrollment130 participants

Primary Completion—

Lead SponsorGalapagos NV

Data Retrieved2026-04-11 04:14:38.910127+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.